vs
Side-by-side financial comparison of GENMAB A/S (GMAB) and GSK plc (GSK). Click either name above to swap in a different company.
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $925.0M | — | ||
| Q2 24 | $779.0M | — | ||
| Q2 23 | $604.5M | — | ||
| Q2 22 | $458.5M | — |
| Q2 25 | $336.0M | — | ||
| Q2 24 | $203.0M | — | ||
| Q2 23 | $193.6M | — | ||
| Q2 22 | $274.2M | — |
| Q2 25 | 93.8% | — | ||
| Q2 24 | 96.4% | — | ||
| Q2 23 | 99.5% | — | ||
| Q2 22 | — | — |
| Q2 25 | 38.9% | — | ||
| Q2 24 | 30.3% | — | ||
| Q2 23 | 35.2% | — | ||
| Q2 22 | 39.4% | — |
| Q2 25 | 36.3% | — | ||
| Q2 24 | 26.1% | — | ||
| Q2 23 | 32.0% | — | ||
| Q2 22 | 59.8% | — |
| Q2 25 | $5.42 | — | ||
| Q2 24 | $3.13 | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
